News | June 04, 2012

GE, Affibody AB Collaborate on PET Imaging Agent for Breast, Gastric Cancer

June 4, 2012 GE Healthcare signed an agreement with Affibody AB (“Affibody”) to collaborate on the development of a Her2-targeted PET imaging agent, which is scheduled to begin clinical trials later this year.

Future clinical trials will investigate the confirmation of Her2 status in patients with breast cancer recurrence, to determine if Her 2 status changes over time, monitor therapy of patients with metastatic breast cancer receiving anti-Her2 treatments, and help resolve indeterminate Her2 tests. These studies, if positive, could ultimately pave the way for better targeting of anti-Her2 therapies to those patients most likely to benefit.

“The partnership brings together the best of several distinct offerings – GE Healthcare’s market expertise in the global PET market, industrialization and commercialization and Affibody’s expertise in generating high-affinity binders and initial clinical data,” Marivi Mendizabal, head of research for GE Healthcare, medical diagnostics. “We expect a productive collaboration with leading academics and the pharma industry to help this research reach its full potential.”

“We are very pleased to continue our relationship with GE Healthcare from the preclinical to the clinical setting and look forward to collaborating with a world-leading partner”, commented David Bejker, CEO of Affibody. “Our clinical data, the first of which was presented at the 34th San Antonio Breast Cancer Symposium last December, is the result of collaborative research with leading academics and has led us to believe that a Her2-targeted PET imaging agent may benefit many cancer patients.”

For more information: www.gehealthcare.com, www.affibody.se

Related Content

Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Breast Density Advocate Nancy M. Cappello Passes Away

Nancy Cappello. Image courtesy of AreYouDense.org.

News | Breast Density | November 15, 2018 | Jeff Zagoudis, Associate Editor
Imaging Technology News extends its condolences to the family, friends and colleagues of Nancy M. Cappello, Ph.D., who...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...